Cheap Cialis Blogger | Search results for "rejects"

RTI Changing the Line We Ferret out Tutelage Disabilities CEC's Representative Playgoers Tackles Theory as well Theory Scrapes at Throng Evidence-based routine Evidence-Based Procedure -- Wanted, Rightful, as well Hard to Gravy CEC Evidence-Based Professional Schemas Proposal Viable dossier thanks to students with disabilities New Underdogs Maintenance Educators Nurse the Best Assistive Technology Technology -- The Excessive Equalizer Special-education teacher shrinkage Shoot Calls owing to Special Breeding Reform Teacher Retention additionally Recruitment Disproportionate total Signature Fosters Guidelines to Reduce Disproportionate Sign New Get down Verifies the Disproportionate Reiteration of Students from Incommensurable Cultures within Definite Learning Five Strategies to Reduce the Overrepresentation of Students from Colorful Cultures amidst Characteristic Edification Identical Also gifted finish funding CEC Rejects Information Chapters Gifted System At-Risk From the CEC Smart Note

Tags: cec, special, disproportionate, evidence, students

It's official sports fans - FDA rejects Arcoxia.

Tags: arcoxia, fda, rejects, fans, sports

In an article in 307 Science 1566 (March 11, 2005) [Patents on Human Genes], Jordan Paradise, Lori Andrews, and Timothy Holbrook of Chicago-Kent wrote: The USPTO could also revamp financial incentives to promote decisions based on the quality of the patents rather than their quantity. Currently, patent examiners are encouraged with monetary bonuses to grant patent applications, a policy that has the unsettling effect of rewarding examiners for quickly pushing patents through the patent office. Specifically, each patent examiner receives a salary bonus based on how many final allowances or rejections of a patent he or she authorizes. Because a rejection can be challenged and may not become final for quite some time, it is easier to receive a bonus by allowing patents. (citing to Merges, Berk Tech L J, 14, 577 (1999)). If examiners were rewarded for granting patents that adhered to patentability requirements (or were held accountable for issuing patents that do not adhere to the requirements), possibly measured by the number of awarded patents that were later upheld in litigation or reexamination procedures, the number of problematic gene patents might significantly decrease. There is the following response: The issue of whether patent examiners are more easily rewarded for "pushing patents through the patent office" is a combination of myth, misunderstanding, and misinformation. Notwithstanding the allegations that patent examiners just issue the applications to receive their bonus awards, not one shred of evidence has been produced to support this position. In fact, this myth is based upon a misunderstanding of the examiner award system. For any award to be received, the examiner must be satisfactory in quality. The Office has implemented a series of review processes that look at both rejected and allowed applications including the Office of Patent Quality Assurance, the in-process review program, the second-pair-of-eyes program, random Supervisor reviews, daily signing of work by the Supervisor, and periodic performance reviews by the Supervisor. If an examiner submits an action, either allowed or rejected, that is clearly improper and that action is reviewed, the examiner's work is sampled until it is determined that the error was an aberration or a pattern of errors is found. Should a pattern of errors be found, the examiner is subject a review process that may result in their removal from the Federal Service. Does it really seem credible that a number of examiners would put a "$100,000 job on the line" for a several thousand dollar award. If anything is true, examiners do all they can to avoid errors and the accompanying additional reviews of their work. Further, the statement "push patents through the patent office" evidences a lack of understanding that almost all patent examiners put extra effort into the allowance of an application. When an examiner can not reject a claim and feels that there should be "some prior art" on this concept, they regularly consult with their peers on whether they have seen such prior art or is that claim actually patentable. In fact, under your description the easiest allowance would be the first action allowance. This is where an examiner would receive both the first action and disposal credit for the same office action; a double count. The statistics show these to be smallest percentage of all first actions issued by the examiners. It is usually in these actions that the examiners may spend the most time of any action to be sure they have not missed some relevant information. The allegation is truly a slur on the professionalism of the USPTO examiners, as mindless drones just working for the money. Finally, the concept "push patents through the patent office" by allowing applications fails to take into consideration that after a first Office action that rejects all of the claims, the applicant may "abandon" the application. Whereas allowing an application takes time, including updating the search, considering the amendments, completing the allowance notice and other documents, to complete the credit for an abandonment takes only a few minutes. Accordingly, there is no easier way to get the credit and potential bonus than by finding the very best art that convinces the applicant that they should not proceed. Even assuming arguendo, that the applicant persists, the examiner is in the best position to conclude the prosecution in the next Office action. It is a complete examination on the first office action that is the easiest way to earn a bonus for the additional work. Finally, the proposal that examiners should be rewarded bonus money based upon the number of patents later upheld in litigation or on reexamination is just plain impractical. Litigation and reexamination proceedings are almost conducted years after the original patent is examined by the examiner. Additionally, the grounds upon which the patent may be invalidated or amended in reexamination may have nothing to do with the work by the examiner. It is hard to imagine an "incentive award system" for patent examiners to help with the Office workload that is premised upon a delay of many years and those outcomes. [the response is not by LBE] generic cialis cialis cheap viagra Cheap Viagra

Tags: patent, examiner, action, office, application

During the second game of the World Series, Fox television commentators early-on pointed to discoloration at the base of Kenny Rogers' left thumb and raised the specter of a foreign substance. The commentators noted that St. Louis, which would be watching the Fox broadcast, would be all over this. Such does not seem to be the case. from the Guardian: Television replay close-ups showed discoloration at the bottom of Rogers' thumb during the opening frame. Rogers cleaned his hand before taking the mound to start the second inning and pitched seven more shutout innings in Detroit's win that tied the best-of-seven championship at 1-1. "What got my attention was guys that came down and said, 'Man, this thing is real obvious on his hand,'" La Russa told reporters at a news conference at Busch Stadium. "I didn't see it. But I did watch video of the other postseason games, so I had an idea of what it looked like, and I said, let's get rid of it and keep playing. LaRussa, who went to law school at Florida State University, talked about the ethics: La Russa spoke about the ethics of the question. "Just because there's a little something that they're using to get a better grip, that doesn't cross the line, you know," La Russa said. "There's a line that I think that defines the competition. "And you can sneak over the line, because we're all fighting for the edge. I always think, does it go to the point of abuse?" said La Russa, who holds a law degree. In contrast to LaRussa's NOT looking at the television, Rogers (according to the Boston Globe) was aware of what was being said on television: But that's Rogers's story and he's sticking to it. He also said he wiped his hand off because he saw on TV that they were talking about it, not because he was instructed to do so by plate umpire Alfonso Marquez. "I think once I wiped the mud off, the last seven innings were very good," Rogers said, "but I'm sure that will be lost in translation with everything." **** While the issue of discoloration on Rogers' hand will come and go quickly, the proposed changes in rules at the USPTO linger like the slow flow of molasses. A hit came up on news.google on Oct. 24 that began: In an effort to streamline the patenting process, the US Patent and Trademark Office (USPTO) is proposing two rule changes that, patent and other experts say, may end up adding cost and time for biotech companies and universities looking to obtain patents on their life science discoveries. The hit ENDED with text: While no public hearings are planned, and the USPTO has wide discretion to change the rules, the agency has been holding a series of "town hall" meetings around the country to explain the proposed rules changes. Additionally, those interested in submitting comments to USPTO can do so by mail until May 3, 2006 . In between, one had some quotes: "Most universities will be dismayed," says Carl E. Gulbrandsen, managing director of the Wisconsin Alumni Research Foundation, the tech transfer office of the University of Wisconsin-Madison. "At universities, even more so than startup biotech companies, the technology that comes off the bench is very early-stage, and often you need several continuations to understand what the invention is and its full breadth," says Gulbrandsen. Doll rejects this logic. "I have absolutely no sympathy for that because when you file an application, that invention is supposed to be complete," he says. "We are being reasonable, [the refiling process has] been a burden on the examiners." But, he continues, if applicants really do need more continuations "and can show a good and sufficient need, we will grant them." However, says Nancy J. Linck, deputy general counsel for intellectual property and trade at the Biotechnology Industry Organization trade association in Washington, DC, the biotech industry relies on continuation practice. "This [proposed] requirement just puts an increased burden on them." The URL is http://www.the-scientist.com/article/display/23177/ See also 88 JPTOS 743 (Sept. 2006). **UPDATE on Oct. 27** Jeff Ferguson wrote: For the first inning Sunday night, Detroit Tigers pitcher Kenny Rogers had what looked to be a foreign substance Generic Viagra cialis cheap viagra generic viagra online

Tags: rogers, rule, television, uspto, inning